Bloomberg the Company

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Regeneron Pharmaceuticals Inc

+ Add to Watchlist


413.170 USD 2.570 0.62%

As of 10:39:37 ET on 01/28/2015.

Snapshot for Regeneron Pharmaceuticals Inc (REGN)

Open: 417.640 Day's Range: 412.830 - 420.600 Volume: 191,787
Previous Close: 415.740 52wk Range: 269.500 - 437.638 1-Yr Rtn: +48.26%

Stock Chart for REGN

No chart data available.
  • REGN:US 412.850
  • 1D
  • 1M
  • 1Y
Interactive REGN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for REGN

Current P/E Ratio (ttm) 136.8375
Estimated P/E(12/2014) 41.4497
Relative P/E vs. SPX 7.6166
Earnings Per Share (USD) (ttm) 3.0382
Est. EPS (USD) (12/2014) 10.0300
Est. PEG Ratio 2.1829
Market Cap (M USD) 42,266.32
Shares Outstanding (M) 99.69
30 Day Average Volume 882,566
Price/Book (mrq) 16.5458
Price/Sale (ttm) 15.6859
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 02/10/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for REGN

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for REGN

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders.

Leonard S Schleifer "Len"President/CEO/Co-FounderGeorge D YancopoulosPres:Laboratories
Joseph J Larosa "Joe"Senior VP/Secy/General CounselDaniel P Van PlewSenior VP/Gen Mgr:Industrial Ops
More Company Profile & Key Executives for REGN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil